Candidate predictive biomarkers to date include elevated CRP in pancreatic and breast cancers, PTPRT/D mutations in HNC, and a JAK1 S703I mutation in HCC, and assessments of biologically plausible biomarkers that predict clinical responses are needed[40,54,55,89,91]. The gene discussed is PTPRT; the disease is hepatocellular carcinoma.